All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-09-17T10:12:15.000Z

Galinpepimut-S granted orphan drug designation by the EMA

Sep 17, 2018
Share:

Bookmark this article

On 13 September 2018, the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) announced that it was to grant Galinpepimut-S (GPS) orphan drug designation, for the treatment of patients with multiple myeloma (MM). This follows fast track designation and orphan drug designation granted by the US Food and Drug Administration (FDA) in July.

GPS targets the Wilms Tumor 1 (WT1) protein present in a number of tumor types and is manufactured by SELLAS Life Sciences (SLS). The product acts as a therapeutic vaccine which stimulates immune activation, and is thought will be beneficial when administered alongside backbone therapies.

This decision is based on data from a phase II trial, in which patients (pts) with high-risk MM were immunized following autologous stem cell transplant (ASCT). Pts administered the vaccine had a median progression-free survival advantage of 11 months, compared to a similar cohort of pts, and the median overall survival (OS) has not yet been reached.

The data was presented at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation earlier this year – see previous MM Hub article. Phase III trials are now likely to follow to further examine efficacy in MM pts, as well as a number of other indications.

More about...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox